Industry News

Topical Botulinum Toxin Moves Forward With New Funding

Topical Botulinum Toxin Moves Forward With New Funding

Anterios, a privately held aesthetic medicine and medical dermatology biopharmaceutical company, has received $8.5 million in corporate financing, which will be used to further development of its patented topical botulinum toxin type A treatment, ANT-1207. Anterios is currently conducting Phase 2b clinical trials of ANT-1207 for clinical indications, including the treatment of lateral canthal lines, hyperhidrosis and acne. Anterios previously completed multi-center, double-blind, randomized, controlled, dose-escalation studies for each indication.

Galderma and AAD Announce Translational Research Fellowship

Physicians play an integral role in pharmaceutical development. And in an effort to support residents who have an interest in drug and product development, the American Academy of Dermatology (AAD), in partnership with Galderma Research & Development, has launched the American Academy of Dermatology Translational Biotechnology Fellowship. The new fellowship will offer dermatologists the opportunity to work in drug development and translational medical research at Galderma's R&D facility located in Sophia Antipolis, France.

LaRoche-Posay Research Award Winners Announced

LaRoche-Posay Research Award Winners Announced

La Roche-Posay has announced the winners of its North American Foundation 2013 Research Awards. This year, three winners were chosen to continue their research in the field of clinical, biological or pharmacological research linked to dermatology: Anna De Benedetto received the first place grant of $10,000, while Patricia Oyetakin-White and Cindy Bae-Harboe were named the second and third place winners respectively, and each received a $5,000 grant.

Cynosure To Acquire Palomar Medical

Aesthetic device manufacturers Cynosure and Palomar Medical Technologies have signed a definitive agreement, pursuant to which Cynosure will acquire Palomar in a cash and stock transaction valued at approximately $294 million. The two companies, which are both based in Massachusetts, report a total combined installed base of more than 20,000 aesthetic laser systems worldwide, with a distribution network that spans more than 100 countries.

La Roche-Posay Introduces "Dermatologist from the Heart" Grant Program

La Roche-Posay has launched the "Dermatologist from the Heart,” a grant program that aims to support initiatives designed to enhance the quality of life of patients. The company will award $10,000 to the most compassionate project—spearheaded by a dermatologist—that seeks to enhance the quality of life of patients. In order to be considered, entrants must submit a grant proposal to the La Fondation La Roche-Posay outlining their projects, which should fall under one of the following five categories:

Savings Vs. Safety

The FDA is cracking down on physicians who purchase injectables from non-U.S. suppliers.
The FDA is cracking down on physicians who purchase injectables from non-U.S. su

Attendees at the January American Academy of Cosmetic Surgery Annual Scientific Meeting in Las Vegas were buzzing about the cautionary tale related by Andrew S. Ittleman, Esq. in his presentation “Doctors’ Use of Foreign-Sourced Injectables.” Ittleman, a founder and partner with the law firm Fuerst Ittleman David & Joseph in Miami, Florida, specializes in complex disputes with the United States government, including the Food and Drug Administration.

Valeant To Acquire Obagi Medical

Valeant Pharmaceuticals International has entered into a definitive agreement to acquire Obagi Medical Products. Under the terms of the agreement, Valeant will acquire all of the outstanding common stock of Obagi Medical Products for $19.75 per share in cash. The transaction is expected to close in the first half of 2013.
Obagi Medical Products is a leader in topical aesthetic and therapeutic skin-health systems with a product portfolio that includes leading dermatology brands including Obagi Nu-Derm, Condition & Enhance, Obagi-C Rx, ELASTIDerm and CLENZIDerm.

New Leaders Take Office at AAD

The American Academy of Dermatology has introduced its new officers, who began their terms on March 5 at the conclusion of the AAD’s 71st Annual Meeting in Miami. Dirk M. Elston, MD, FAAD, is now president of the AAD. He received his medical degree from Thomas Jefferson University Medical School in Philadelphia and is a past director of the department of dermatology at Geisinger Medical Center in Danville, Pennsylvania and the current director of the Ackerman Academy of Dermatopathology in New York. Dr. Elston will hold office for one year and is joined by vice president Lisa A.